← Back to Search

Vasodilator

13.6 % Oxygen and Inhaled Nitric Oxide for Hypoxia (iNO Trial)

Phase 1 & 2
Waitlist Available
Led By Micahel Stickland, PhD
Research Sponsored by University of Alberta
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Young healthy males and females with normal lung function and no known history of cardiopulmonary disease.
Non-smokers and less than 10 pack years smoking history
Timeline
Screening 3 weeks
Treatment Varies
Follow Up within 20-25 minutes post-dose
Awards & highlights

iNO Trial Summary

This trial is testing whether inhaled nitric oxide can help people exercise better in low-oxygen conditions, like at high altitudes.

iNO Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

iNO Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~within 20-25 minutes post-dose
This trial's timeline: 3 weeks for screening, Varies for treatment, and within 20-25 minutes post-dose for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Exercise Capacity
Secondary outcome measures
Cardiac Output
Pulmonary artery pressure

iNO Trial Design

4Treatment groups
Experimental Treatment
Placebo Group
Group I: 13.6 % Oxygen and Inhaled Nitric OxideExperimental Treatment1 Intervention
Severe level of hypoxia (13.6% Oxygen) and Inhaled Nitric Oxide (40 ppm)
Group II: 12.1% Oxygen and Inhaled Nitric OxideExperimental Treatment1 Intervention
Moderate level of hypoxia (12.1% Oxygen) and Inhaled Nitric Oxide (40 ppm)
Group III: 12.1 % Oxygen PlaceboPlacebo Group1 Intervention
Moderate level of hypoxia (12.1 % Oxygen) and Placebo (0 ppm Nitric Oxide)
Group IV: 13.6 % Oxygen and PlaceboPlacebo Group1 Intervention
Severe level of hypoxia (13.6% Oxygen) and Placebo (0 ppm Nitric Oxide)
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Nitric Oxide
2004
Completed Phase 4
~1280

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

University of AlbertaLead Sponsor
884 Previous Clinical Trials
393,040 Total Patients Enrolled
4 Trials studying Hypoxia
2,670 Patients Enrolled for Hypoxia
Micahel Stickland, PhDPrincipal InvestigatorUniversity of Alberta

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
~4 spots leftby Mar 2025